Evidence map›Paper›PMID 31286231›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

The pathogenesis of mucositis: updated perspectives and emerging targets.

J Bowen, N Al-Dasooqi, P Bossi, H Wardill, Y Van Sebille, A Al-Azri, E Bateman, M E Correa, J Raber-Durlacher, A Kandwal and 10 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  9. Guideline
  10. Trial
  11. Hangeshashinto for prevention of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a randomized phase II study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Impact of structured oral care strategies on oral mucositis in patients receiving 5-fluorouracil: a retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  19. Article
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

J BowenAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia. joanne.bowen@adelaide.edu.au.ORCID http://orcid.org/0000-0003-0876-0031
N Al-DasooqiAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
P BossiDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health - Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia, Italy.
H WardillAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
Y Van SebilleDivision of Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
A Al-AzriDental and OMFS Department, Oral Pathology and Medicine, Al-Nahdha Hospital, Ministry of Health, Muscat, Oman.
E BatemanAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
M E CorreaHematology and Blood Transfusion Center, University of Campinas, Campinas, Brazil.
J Raber-DurlacherDepartment of Oral and Maxillofacial Surgery, Amsterdam UMC, and Department of Oral Medicine, Academic Center for Dentistry Amsterdam, University of Amsterdam and VU University, Amsterdam, Netherlands.
A KandwalCancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayn University, Dehradun, Uttarakhand, India.
B MayoDivision of Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
R G NairOral Medicine, Oral Oncology, Oral Pathology and Human Diseases, Griffith University, Hematology and Oncology, Gold Coast University Hospital, Southport, Queensland, Australia.
A StringerDivision of Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
K Ten BohmerOral medicine, Academic Centre Dentistry Amsterdam (ACTA), University of Amsterdam, Amsterdam, Netherlands.
D ThorpeDivision of Health Sciences, University of South Australia, Adelaide, SA, 5001, Australia.
R V LallaSection of Oral Medicine, University of Connecticut Health, Farmington, CT, USA.
S SonisHarvard School of Dental Medicine, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston, MA, USA.
K ChengAlice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
S EladDepartment of Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA.
Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucositis research and treatment are a rapidly evolving field providing constant new avenues of research and potential therapies. The MASCC/ISOO Mucositis Study Group regularly assesses available literature relating to pathogenesis, mechanisms, and novel therapeutic approaches and distils this to summary perspectives and recommendations. Reviewers assessed 164 articles published between January 2011 and June 2016 to identify progress made since the last review and highlight new targets for further investigation. Findings were organized into sections including established and emerging mediators of toxicity, potential insights from technological advances in mucositis research, and perspective. Research momentum is accelerating for mucositis pathogenesis, and with this has come utilization of new models and interventions that target specific mechanisms of injury. Technological advances have the potential to revolutionize the field of mucositis research, although focused effort is needed to move rationally targeted interventions to the clinical setting.

Indexed as

HumansMucositisNeoplasmsStomatitisMicrobiomeMucositisPathogenesisPermeabilityPerspectivesTechnology

Identifiers

PMID31286231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.